{"top_spans": [[0, 1], [1, 1], [2, 2], [5, 5], [8, 8], [14, 14], [14, 19], [14, 20], [17, 17], [17, 19], [20, 20], [22, 22], [22, 26], [23, 26], [26, 26], [27, 30], [27, 34], [28, 31], [28, 34], [29, 34], [32, 32], [38, 39], [40, 40], [41, 41], [50, 50], [51, 52], [51, 54], [58, 58], [66, 66], [69, 71]], "predicted_antecedents": [-1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1, -1], "document": ["ironwood", "pharmaceuticals", "provides", "third", "quarter", "2018", "investor", "update", "cambridge", "mass", "business", "wire", "-nov", "6", "2018-ironwood", "pharmaceuticals", "inc", "nasdaq", "bowel", "syndrome", "cambridge", "olinciguat", "ironwood", "constipation", "abdominal", "pain", "iw-3718", "ironwood", "ironwood", "phase", "iia", "asymptomatic", "ironwood", "pharmaceuticals", "gerd", "diabetic", "nephropathy", "hfpef", "abdominal", "distension", "severe", "diarrhea", "cic", "zurampic", "u", "s", "olinciguat", "peter", "hecht", "praliciguat", "ironwood", "r&d", "co", "allergan", "nephropathy", "fda", "achalasia", "praliciguat", "ironwood", "renal", "disease", "ironwoods", "gaap", "ironwood", "gaap", "allopurinol", "ironwood", "pharmaceuticals", "inc", "astrazeneca", "iw", "3718", "ironwood", "olinciguat", "ironwood", "mass"], "clusters": []}